ライフサイエンスコーパス: WHO classification

1 ing tumour recurrence and prognosis than the WHO classification.

2 ia and OGTT was interpreted according to the WHO classification.

3 an expert pathologic diagnosis according to WHO classification.

4 pathologists and classified according to the WHO classification.

5 Several new studies validate the WHO classification.

6 likely reflects changes in the revised 1999 WHO classification.

7 ountries into six world regions according to WHO classifications.

8 dated in the last World Health Organization (WHO) classification.

9 ption of the 2001 World Health Organization (WHO) classification.

10 according to the World Health Organization (WHO) classification.

11 oups by using the World Health Organization (WHO) classification (11).

12 papillary carcinomas in accordance with the WHO classification and because the identification of pap

13 cases of NHL from 5 CSA countries using the WHO classification and compared them to 400 cases from N

14 Diagnoses were confirmed according to WHO classification and graded as suggested by Jouvet et

15 evance of entities currently included in the WHO classification and that also suggest new entities th

16 recurrent genetic abnormalities according to WHO classification and those with derivative chromosomes

17 xt of the current World Health Organization (WHO) classification and to evaluate the outcome of MK(+)

18 were subcategorized according to the latest WHO classification, and tumor cellularity was calculated

19 ow that histologic criteria described in the WHO classification are difficult to apply reproducibly a

20 lant is also critical, and predictive tools (WHO classification-based prognostic scoring system and h

21 morbidity index) and other predictive tools (WHO classification-based prognostic scoring system), and

22 patients with extranodal NKTCL, nasal type (WHO classification criteria; cases) and 957 controls fro

23 Whereas the WHO classification defines its categories based on histo

24 The WHO classification for well-differentiated pancreatic en

25 6 revision of the World Health Organization (WHO) classification for lymphoma has included a new cate

26 In 2008, the revised WHO classification has expanded this category into "AML

27 The WHO classification has produced a new and exciting degre

28 on adopted by the World Health Organization (WHO) classification has been validated in international

29 According to the WHO classification, Hodgkin's lymphoma (HL) is subdivide

30 mphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the

31 The 4th edition of the WHO classification incorporates new information that has

32 The WHO classification is useful for defining subtypes of PT

33 The WHO classification of brain tumours describes 15 subtype

34 g lesions classified as grade I or II by the WHO classification of CNS tumors.

35 e-control study of severe malaria, using the WHO classification of G6PD mutations to estimate each in

36 logical classification of these lesions, the WHO classification of human tumors was used as a referen

37 inoma and BAC as newly published in the 2004 WHO Classification of Lung Tumors, and to address the pa

38 A major revision of the WHO classification of lymphoid and myeloid neoplasms and

39 this communication is to outline briefly the WHO classification of malignant myeloid diseases, to dra

40 In the current WHO classification of myeloid disorders, chronic neutrop

41 WHO classification of myeloid malignancies is based main

42 e been included in the current update of the WHO classification of myeloid neoplasms and AML, and mut

43 l Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms, who endorsed th

44 ished explanation or rationale given for the WHO classification of the myeloid neoplasms.

45 blished a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Ly

46 The 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymp

47 The guideline is based on the 2016 WHO classification of tumours of the central nervous sys

48 alidated the 2001 World Health Organization (WHO) classification of acute myeloid leukemia (AML), inc

49 fined in the 2008 World Health Organization (WHO) classification of AML.

50 e developed a new World Health Organization (WHO) classification of hematologic malignancies, includi

51 A World Health Organization (WHO) classification of hematopoietic and lymphoid neopla

52 The current World Health Organization (WHO) classification of hematopoietic malignancies define

53 ferences, the new World Health Organization (WHO) classification of lymphoma suggests further subdivi

54 eliability of the World Health Organization (WHO) classification of myelodysplastic syndromes (MDSs)

55 The World Health Organization (WHO) classification of myeloproliferative neoplasms (MPN

56 6 revision of the World Health Organization (WHO) classification of myeloproliferative neoplasms defi

57 The World Health Organization (WHO) classification of tumors of the hematopoietic and l

58 uldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on h

59 lved from the French-American-British to the WHO classification over the last few years.

60 We also wanted to determine if the WHO classification provided additional information about

61 The revised 2008 WHO classification recognizes both molecularly defined (

62 s in the field, with emphasis on the updated WHO classification, refined criteria, additional prognos

63 The WHO classification reliably predicted therapeutic respon

64 This fact should be considered in future WHO classification reviews.

65 The DNA methylation-based and WHO classification schema were compared using the Brier

66 In conclusion, in the 2008 WHO classification scheme, FAB subclassification does no

67 microscopes, classifying slides based on the WHO classification standard of 100 fields of view (FoV)

68 trials (n = 309) with azacitidine using the WHO classification system for MDS and acute myeloid leuk

69 c disease characteristics in the most recent WHO classification system, improved understanding of the

70 nct entity in the World Health Organization (WHO) classification system, is readily recognized as a p

71 agnosis using the World Health Organization (WHO) classification system.

72 The WHO classification, tumor stage, and grade were associat

73 nd mature per the World Health Organization (WHO) classification using CD1a and surface CD3 status.

74 f abnormal glucose tolerance between ADA and WHO classifications were significant (p<0.0001).